Company intelligence / Profile preview

CytoVac A

Hørsholm, Denmark

Ownership: Private
Employees: ~15
Development stage: Other

Overview

CytoVac is a Danish clinical-stage biotechnology company specializing in the development of personalized cancer immunotherapies. The company's core technology is the ALECSAT (Autologous Lymphoid Effector Cells Specific Against Tumor cells) platform, which involves the activation and expansion of a patient's own T cells and Natural Killer (NK) cells to target specific tumor-associated antigens. This multi-effector cell approach is designed to overcome the heterogeneous nature of solid tumors and prevent immune escape. CytoVac is currently advancing its lead programs through Phase 2 clinical trials for aggressive cancers such as glioblastoma and prostate cancer.

Therapeutic areas: Oncology
Modalities: Cell therapyT cell therapyNK cell therapy
Industry: Biotech

Beyond the preview

Go deeper on CytoVac A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoVac A.

Explore the full profile